{"id":"active-comparator-niraparib","safety":{"commonSideEffects":[{"rate":"62","effect":"Thrombocytopenia"},{"rate":"52","effect":"Anemia"},{"rate":"71","effect":"Nausea"},{"rate":"58","effect":"Fatigue"},{"rate":"35","effect":"Vomiting"},{"rate":"26","effect":"Constipation"},{"rate":"30","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL1094636","moleculeType":"Small molecule","molecularWeight":"320.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Niraparib is a PARP inhibitor that blocks PARP1 and PARP2, enzymes responsible for repairing single-strand DNA breaks. By inhibiting PARP, the drug causes accumulation of DNA damage in cancer cells, particularly those with BRCA mutations or homologous recombination deficiency, triggering apoptosis. This mechanism is especially effective in ovarian and other cancers with impaired DNA repair pathways.","oneSentence":"Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:11.768Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Recurrent ovarian cancer (BRCA-mutated and non-mutated)"},{"name":"Maintenance treatment of ovarian cancer following platinum-based chemotherapy"},{"name":"HRD-positive ovarian cancer"}]},"trialDetails":[{"nctId":"NCT01847274","phase":"PHASE3","title":"A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2013-06-21","conditions":"Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer","enrollment":596}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Niraparib"],"phase":"phase_3","status":"active","brandName":"Active comparator: Niraparib","genericName":"Active comparator: Niraparib","companyName":"Tesaro, Inc.","companyId":"tesaro-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death. Used for Recurrent ovarian cancer (BRCA-mutated and non-mutated), Maintenance treatment of ovarian cancer following platinum-based chemotherapy, HRD-positive ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}